12/23
08:06 am
zlab
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia [Yahoo! Finance]
Low
Report
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia [Yahoo! Finance]
12/23
07:30 am
zlab
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
Low
Report
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
12/15
03:31 pm
zlab
Does Zai Lab's Steep 86.2% Slide Mask a Long Term Value Opportunity? [Yahoo! Finance]
Low
Report
Does Zai Lab's Steep 86.2% Slide Mask a Long Term Value Opportunity? [Yahoo! Finance]
12/8
07:00 am
zlab
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Low
Report
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
12/7
12:24 am
zlab
Zai Lab Announces Updates to China's National Reimbursement Drug List [Yahoo! Finance]
Low
Report
Zai Lab Announces Updates to China's National Reimbursement Drug List [Yahoo! Finance]
12/7
12:11 am
zlab
Zai Lab Announces Updates to China’s National Reimbursement Drug List
Low
Report
Zai Lab Announces Updates to China’s National Reimbursement Drug List
11/30
05:51 am
zlab
Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum [Yahoo! Finance]
Low
Report
Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum [Yahoo! Finance]
11/11
12:01 pm
zlab
Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) [Seeking Alpha]
Low
Report
Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) [Seeking Alpha]
11/7
08:19 am
zlab
Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
07:15 am
zlab
Zai Lab Non-GAAP EPS of -$0.33 misses by $0.04, revenue of $116.09M misses by $27.64M [Seeking Alpha]
Low
Report
Zai Lab Non-GAAP EPS of -$0.33 misses by $0.04, revenue of $116.09M misses by $27.64M [Seeking Alpha]
11/6
07:00 am
zlab
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Medium
Report
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
10/31
07:30 am
zlab
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Low
Report
Zai Lab Announces Participation in Investor Conferences in November and December 2025
10/30
08:12 pm
zlab
Zai Lab (NasdaqGM:ZLAB): Exploring Valuation After a 23% One-Month Share Price Decline [Yahoo! Finance]
Low
Report
Zai Lab (NasdaqGM:ZLAB): Exploring Valuation After a 23% One-Month Share Price Decline [Yahoo! Finance]
10/24
12:26 pm
zlab
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/24
09:00 am
zlab
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Medium
Report
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
10/15
07:30 am
zlab
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Medium
Report
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
10/13
12:02 pm
zlab
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Low
Report
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
10/8
12:39 pm
zlab
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
03:48 pm
zlab
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zai Lab (NASDAQ:ZLAB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.